A pilot study on the off-label use of valproic acid to treat adenomyosis
article
OA: bronze
CC0
⤵ 62 in-corpus citations
AI-generated summary
This pilot study investigated the off-label use of valproic acid for adenomyosis and reported its findings.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Following on the heels of the discovery that endometriosis is an epigenetic disease, we conducted a pilot study on the off-label use of valproic acid to treat adenomyosis. We found that by the end of the 3-month treatment, all three recruited patients reported complete disappearance of dysmenorrhea, with an average of one-third reduction in uterus size.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (33)
- Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis via openalex
- Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis via openalex
- Adenomyosis: Not such an elusive diagnosis any longer via openalex
- Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats via openalex
- Inhibition of Proliferation of Endometrial Stromal Cells by Trichostatin A, RU486, CDB-2914, N-Acetylcysteine, and ICI 182780 via openalex
- Medical and surgical management of adenomyosis via openalex
- p16, retinoblastoma (pRb), and cyclin D1 protein expression in human endometriotic and adenomyotic lesions via openalex
- Pathophysiology of adenomyosis via openalex
- Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis via openalex
- Promoter Hypermethylation of Progesterone Receptor Isoform B (PR-B) in Endometriosis via openalex
- The symptomatology of adenomyosis via openalex
- Treatment of adenomyosis with long-term GnRH analogues: a case report. via openalex
- Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds via openalex
- W2117691193 via openalex
- W2123883580 via openalex
- W2138154283 via openalex
- W6602921218 via openalex
- W6607491137 via openalex
- W6635703387 via openalex
- W72984541 via openalex
- doi:10.1016/j.fertnstert.2006.07.705 via openalex
- W1601632081 via openalex
- W1935963841 via openalex
- W1964363319 via openalex
- W1975220342 via openalex
- W2001699192 via openalex
- W2006785548 via openalex
- W2015834221 via openalex
- W2038354928 via openalex
- W2086990722 via openalex
- W2098249941 via openalex
- W2098596663 via openalex
- W2105497865 via openalex
Cited by (50)
- Research Progress of Histone Deacetylase and Its Inhibitors in Endometriosis 2026
- Adenomyosis: Unravelling the causes and exploring treatment strategies among patients seeking conception 2025
- Drug development for adenomyosis based on pathophysiology 2025
- Consider fertility-preserving medications when treating adenomyosis 2024
- Meclizine improves endometrial repair and reduces simulated menstrual bleeding in mice with induced adenomyosis 2024
- Hypercoagulability in women with adenomyosis who experience heavy menstrual bleeding 2023
- Aberrant expression of histone deacetylase 8 in endometriosis and its potential as a therapeutic target 2023
- The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review 2023
- Evaluation of Endpoints Used in Clinical Trials on Adenomyosis - A Systematic Review 2023
- Corroborating evidence for aberrant expression of histone deacetylase 8 in endometriosis 2023
- Genetics and genomics of endometriosis☆ 2023
- The Role of Platelets in the Pathogenesis and Pathophysiology of Adenomyosis 2023
- Insights on Adenomyosis Development 2022
- Medical Treatment of Adenomyosis 2022
- Endometriosis Research: From Bench to Bedside 2022
- Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology 2022
- Adenomyosis: Mechanisms and Pathogenesis 2020
- An Update on the Various Theories of the Origin of Uterine Adenomyosis –A Systematic Review 2020
- A critical review of recent advances in the diagnosis, classification, and management of uterine adenomyosis 2019
- Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology 2019
- Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going? 2019
- The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights 2019
- The role of oxytocin in the pathogenesis of endometriosis: various aspects of the problem 2019
- Genetics and Genomics of Endometriosis 2018
- Investigational drugs for the treatment of endometriosis, an update on recent developments 2018
- Pathogenesis of uterine adenomyosis: invagination or metaplasia? 2018
- Current and emerging treatment options for endometriosis 2018
- Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis 2018
- Traitement médical de l’endométriose : prise en charge de la douleur et de l’évolution des lésions par traitement hormonal et perspectives thérapeutiques 2017
- Pathogenesis of adenomyosis: an update on molecular mechanisms 2017
- Revisiting the wandering womb: Oxytocin in endometriosis and bipolar disorder 2017
- Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis 2017
- Ali Farid’s Updated Innovation in Women Reproduction 2016
- Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence 2016
- Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis 2016
- Platelet-derived TGF-β1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis 2016
- An overview of early drug development for endometriosis 2015
- Novel Medical Treatment Modalities of Endometriosis 2015
- On-label and off-label drug use in the treatment of endometriosis 2015
- On-label and off-label drug use in the treatment of endometriosis 2015
- Medical Treatments for Endometriosis-Associated Pelvic Pain 2014
- Potential Mechanisms of an Antiadenomyosis Chinese Herbal Formula Shaoyao‐Gancao Decoction in Primary Cell Culture Model 2014
- A pilot study on the use of andrographolide to treat symptomatic adenomyosis 2014
- Potential New Drugs for Endometriosis: Experimental Evidence 2014
- Aberrant histone modification in endometriosis 2014
- Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells 2013
- Консенсус по ведению эндометриоза 2013
- Consensus on current management of endometriosis 2013
- Consensus on current management of endometriosis 2013
- Methodological Issues in Preclinical Mouse Efficacy Studies of Adenomyosis 2012
Source provenance
- europepmc
- last seen: 2026-10-07T06:10:45.703000+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:15:06.633332+00:00
License: CC0
· commercial use OK